A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections.
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Moxifloxacin (Primary) ; Moxifloxacin (Primary) ; Amoxicillin/clavulanic acid; Piperacillin/tazobactam
- Indications Abscess; Bacterial skin diseases; Cellulitis; Diabetic foot ulcer; Escherichia coli infections; Skin and soft tissue infections; Staphylococcal infections
- Focus Registrational; Therapeutic Use
- Acronyms RELIEF
- Sponsors Bayer; Bayer HealthCare
- 31 Aug 2018 Biomarkers information updated
- 24 Sep 2010 Results from a sub-study in patients with diabetic foot infections were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
- 13 Apr 2010 Results from a sub-study in patients with diabetic foot ulcer have been presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History